Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
According to Golden Ten Data APP, Iambic Therapeutics (IAM.US), a clinical-stage biotechnology company based in San Diego, California that develops small molecule anti-cancer therapies using its proprietary artificial intelligence (AI) platform, announced its IPO terms on Thursday. The company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 per share. Some investors have indicated interest in subscribing for $60 million worth of shares in this offering (accounting for 40% of the transaction). Based on the midpoint of the proposed price range, Iambic Therapeutics’ fully diluted market capitalization would reach $809 million.
Iambic Therapeutics is a clinical-stage biotechnology company that combines proprietary AI models with automated high-throughput chemistry and biology to design small molecule drugs. The platform operates a closed-loop process: its models propose compound candidates, the robotic lab synthesizes and tests hundreds of compounds for each project weekly, and the resulting data is used to retrain the models. Its main drug candidate, IAM1363, is a selective, blood-brain barrier-penetrant HER2 inhibitor, currently undergoing Phase 1/1b clinical trials for HER2-altered solid tumors, with registrational trials potentially beginning as early as 2027; two other preclinical projects targeting KIF18A and CDK2/4 are planned to submit IND applications in the fourth quarter. To date, Iambic Therapeutics has generated revenue through collaborations with companies such as AbbVie (ABBV.US), Takeda Pharmaceuticals (TAK.US), and Bayer (BAYRY.US).
Iambic Therapeutics was founded in 2019 and achieved $18 million in revenue over the 12 months ending June 30, 2026. The company plans to list on Nasdaq under the ticker IAM. JPMorgan, Jefferies, BofA Securities, and Citi are serving as joint bookrunners for this offering. Pricing is expected during the week of October 12, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
EUR/USD Price Forecast: Rallies fail above 1.1200 amid high Oil prices, debt woes
The strongest growth outlook in over two years is approaching! US medical device stocks still need to endure another sluggish earnings season
The third-quarter profit growth of medical device companies is expected to be only 4.8%, but it is projected to accelerate to 13% in the first quarter of next year, marking the strongest performance in over two years. However, policy uncertainties and product recalls have dampened confidence, and the market is awaiting a recovery by 2027.
BUZZ—US Stock Market Dynamics: SpaceX, Humana, Delta Air Lines
Workspace search string for querying individual stock trends: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Brief": https://refini.tv/3dKUyB8 Reuters, October 9 — On Friday, U.S. stock index futures rose as oil prices retreated due to easing concerns over Middle East supply. However, telecom stocks remained under pressure as SpaceX's acquisition of spectrum sparked competition concerns across the telecom sector. - **T-Mobile US Inc (TMUS.O):** Hot topic — European telecom stocks fell after the SpaceX spectrum deal. [nL6N45V0EH] - **Space Exploration Technologies Corp (SPCX.O):** Hot topic — Shares rose after reaching an agreement to acquire a nationwide low-band spectrum portfolio. [nL4N45V0KP] - **Humana Inc (HUM.N):** Hot topic — Shares rose after its “Medicare Advantage” rating was raised. [nL4N45V0LU] - **Definium Therapeutics Inc (DFTX.O):** Market buzz — Shares increased after JPMorgan gave its LSD-based therapy an “Overweight” rating. [nL4N45V0NH] - **UnitedHealth Group Inc (UNH.N):** Market movement — TD Cowen lowered its target price ahead of UnitedHealth’s Q3 financial report. [nL4N45V0OU] - **Newmont Corporation (NEM.N):** - **Gold Fields Ltd (GFI.N):** - **Harmony Gold Mining Company Limited (HMY.N):** - **AngloGold Ashanti Ltd (AU.N):** Market movement — Gold miners’ shares rose in line with a slight rise in gold prices driven by a weaker dollar. [nL4N45V0PG] - **Delta Air Lines Inc (DAL.N):** Market flash — Shares fell after sharply lowering full-year profit forecast. [nL4N45V0RA] - **Apple Inc (AAPL.O):** Hot topic — Shares declined amid reports of iPhone production cuts. [nL4N45V0SB] - **Crescent Energy Company (CRGY.N):** Hot topic — Shares fell after raising 1 billion USD to acquire Devon Energy. [nL6N45V0J4] (For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. As automated translations may contain errors or may not capture the necessary context, Reuters does not guarantee the accuracy of the automated translation text, which is provided solely for readers’ convenience. Reuters accepts no liability for any damage or loss caused by the use of this function.)
BlackRock trims TAG Immobilien voting rights to 6.68% from 6.81%
BlackRock cut its total TAG voting rights to 6.68% from 6.81% on Oct. 6, 2026. Equity stake rose to 5.15% from 4.71%. Positions via instruments fell to 1.54% from 2.10%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TAG Immobilien AG published the original content used to generate this news brief via EQS News (Ref. ID: PVR_2413388_en) on October 09, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
